The Role of Epigenetic Modifications and HDAC Inhibitors in Glioblastoma Multiforme (GBM)

Rashmitha Bathina

Introduction

Glioblastoma Multiforme (GBM) is one of the most formidable forms of brain tumors due to its highly aggressive nature, rapid proliferation, and resistance to conventional therapies. Histone deacetylases (HDACs) regulate chromatin structure and gene expression, and they have been associated with the silencing of tumor suppressor genes and promotion of cell survival.

Although HDAC inhibition has shown some promise in preclinical studies, the specific mechanisms through which HDACs influence GBM cell behavior and the most effective strategies for HDAC inhibition remain poorly understood. There is a lack of research surrounding the optimal conditions for therapeutic efficiency of HDACs for cancer and a lack of comprehensive understanding of how HDACs impact GBM cell proliferation, survival, and gene expression.There is a lack of comprehensive understanding regarding how inhibiting HDACs impacts GBM cell proliferation, survival, and gene expression, as well as the optimal conditions for therapeutic efficacy. This study will evaluate the effect of HDAC inhibition on GBM cells, characterize the changes in gene expression following HDAC inhibition, and investigate the mechanisms of apoptosis induced by HDAC inhibition.

Despite the reach of the study, there are three future directions to be further researched. The first knowledge gap to be identified is HDAC inhibitors in combination with other therapies, such as radiation or targeted therapies, in order to enhance the efficacy of HDAC inhibitors. There must also be an evaluation of the efficacy, safety, and implementation of HDAC inhibitors in more complex animal and human models to determine potential clinical reliance. It is also important to identify biomarkers that predict response to HDAC inhibition to enable doctors to create personalized treatment approaches based on individual patient profiles.

Main Body

Glioblastoma Multiforme (GBM) is the most aggressive and lethal form of primary brain tumor. This disease is characterized by rapid proliferation, invasiveness, and cells that are resistant to regular cancer therapies such as surgery, radiation, and chemotherapy (Lee et al., 2015). Such an aggressive disease leads to the mortality rate for patients being only 12 to 15 months, making it one of the most difficult cancer diagnoses. Recent research has linked to a possible role of modifying epigenetics to drive GMB tumorigenesis and therapeutic resistance in patients (Bender et al., 2013). Epigenetics refers to changes in gene expression that do not involve alterations to the underlying DNA sequence. One way this is commonly done is by DNA methylation which is the addition of a methyl group to DNA. In GBM, however, abnormal DNA methylation patterns can silence tumor suppressor genes and activate oncogenes, contributing to uncontrolled cell growth (Hegi et al., 2005). Another method of epigenetic modification is histone modification where the protein around with DNA is wound (called histones) form a structure called chromatin. Chemical modifications to histones, such as acetylation and deacetylation, can change the accessibility of DNA to transcription machinery, which can help in regulating cancer through gene expression (Chen et al., 2020).

Histone deacetylases (HDACs) work to regulate chromatin structure and gene expression. They have the ability to influence cell cycle progression and apoptosis which are

key components of how cells in general grow and are signaled to die. Histone deacetylases (HDACs) are enzymes and they remove acetyl groups from histones, leading to a more compact and transcriptionally repressed chromatin structure. In recent studies, overactivity of HDACs has indicated that the genes that control cell cycle arrest and apoptosis are silenced (Bender et al., 2013). For example, in a study by Dr. Lee from Medical University of South Carolina, HDAC inhibitors were applied to GBM cell lines, leading to a significant reduction in cell proliferation and an increase in apoptosis Lee et al. (2015). The results showed that HDAC inhibition reactivated silenced tumor suppressor genes, which then worked to promote cell cycle arrest and programmed cell death, suggesting a promising therapeutic approach for GBM treatment. This indicates HDACs have potential in decreasing tumor growth and promoting survival for GBM patients.

Furthermore, abnormal HDAC activity has a potential linkage to maintaining a malignant phenotype of GMB, which suggests that targeting HDACs is a valuable potential therapeutic strategy. The inhibition of specific HDACs, may possibly disrupt the epigenetics of GBM cells, which result in a lack of tumor growth and cancerous cells being more inclined to apoptosis (Trang Huyen Nguyen et al., 2020). This approach may allow us to uncover novel epigenetic targets and therapeutic avenues that may help in the objective of creating improved treatment outcomes for GBM patients.

Conclusion and Future Directions

After we see the impact of HDAC inhibitors on GBM cells, the next step is to find ways to optimize these inhibitors to work even better. One idea may be to combine HDAC inhibitors in tandem with other treatments, like radiation to kill more cancer cells or targeted therapies that attack specific parts of cancer cells. Once again, testing different combinations of treatments may help identify which strategies are most effective in stopping GBM cell growth and survival. Results from cell studies may be promising however results must also be mirrored in complex organisms through In Vivo testing. By testing the HDAC inhibitors in animal models of GBM, researchers can check effectiveness and safety within more complex biological systems, which can prove effectiveness in actual human patients. This future step would determine if the inhibitors can actually shrink tumors and prolong survival in a living organism. It will also help bring to light any potential side effects which are important to consider in the process of developing safe treatments for patients.

Since not all patients may respond to epigenetic modifications and HDACs in the same way, it will be important to identify which patients will benefit the most from HDAC inhibitors. Perhaps looking for biomarkers will help predict how well a patient will respond to treatment and allow GBM patients to receive personalized treatment plans. If these biomarkers can be identified, doctors will be able to choose the most effective treatments for each patient based on their unique biological profile. This personalized approach can improve treatment outcomes and reduce unnecessary side effects.

Thus, the role of epigenetic modifications and HDAC inhibitors in Glioblastoma Multiforme (GBM) represents a promising frontier in neuro-oncology. By targeting the epigenetic mechanisms that drive tumor growth and resistance, HDAC inhibitors have the potential to disrupt the malignant phenotype of GBM cells, thereby improving treatment outcomes. Future research focusing on combination therapies, in vivo testing, and the identification of predictive biomarkers will be crucial in advancing HDAC inhibitors from preclinical studies to clinical applications. Through these efforts, we may develop more effective, personalized treatment

strategies that enhance the survival and quality of life for patients battling this form of brain cancer.

References

Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., ... & Lichter, P. (2013). Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant gliomas. Nature Genetics, 45(6), 626-630. https://doi.org/10.1038/ng.2605

Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020). The application of histone deacetylases inhibitors in glioblastoma. Journal of Experimental & Clinical Cancer Research, 39(1). https://doi.org/10.1186/s13046-020-01643-6

Chinnaiyan, P., Kensicki, E., Bloom, G., Prabhu, A., Sarcar, B., Kahali, S., ... & Chakravarti, A. (2012). The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Research, 72(22), 5878-5888. https://doi.org/10.1158/0008-5472.CAN-12-0858

Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., ... & Stupp, R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997-1003. https://doi.org/10.1056/NEJMoa043331

Kim, E. L., Wüstenberg, R., Rubsam, B., Schmid, K. W., Sabel, M. C., Sperling, S., ... & Kampe, B. (2011). Nimotuzumab inhibits the epidermal growth factor receptor in glioma cells of

established and primary cultures, but induces apoptosis only in established cell lines. Cancer Research, 71(8), 2351-2359. https://doi.org/10.1158/0008-5472.CAN-10-2588

Lee, D. H., Ryu, H.-W., Won, H.-R., & Kwon, S. H. (2017). Advances in epigenetic glioblastoma therapy. Oncotarget, 8(11), 18577–18589. https://doi.org/10.18632/oncotarget.14612

Lee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S. M., Varma, A. K., Vandergrift, W. A., Patel, S. J., & Das, A. (2015). Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy. Anticancer Research, 35(2), 615–625. https://ar.iiarjournals.org/content/35/2/615.short

Patel, M., & Ahmed, S. (2011). Epigenetic regulators in glioblastoma multiforme: The drivers of GSC phenotype. Cancer Research, 71(22), 7210-7217. https://doi.org/10.1158/0008-5472.CAN-11-1332

Trang Huyen Nguyen, Zhang, Y., Shang, E., Shu, C., Torrini, C., Zhao, J., Bianchetti, E., Mela, A., Humala, N., Mahajan, A., Arif Harmanci, Lei, Z., Maienschein-Cline, M., Quinzii, C. M., Westhoff, M.-A., Georg Karpel-Massler, Bruce, J. N., Canoll, P., & Siegelin, M. D. (2020). HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. 130(7), 3699–3716. https://doi.org/10.1172/jci129049

Yelton, C. J., & Ray, S. K. (2018). Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma. Neuroimmunology and Neuroinflammation, 5(11), 46. https://doi.org/10.20517/2347-8659.2018.58